Your browser doesn't support javascript.
loading
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2.
Barley, Kevin; Sanchez, Larysa; Cho, Hearn J; Parekh, Samir; Madduri, Deepu; Richter, Joshua; Isola, Luis; Goldstein, Talia; Dhadwal, Amishi; Zarychta, Katarzyna; Sanchez, Gillian Morgan; Catamero, Donna; Verina, Daniel; Florendo, Erika; Yum, Moon-Hee; La, Lisa; Gullie, Jude; Chan, Elaine; Jagannath, Sundar; Chari, Ajai.
Afiliação
  • Barley K; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Sanchez L; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Cho HJ; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Parekh S; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Madduri D; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Richter J; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Isola L; Bone Marrow and Stem Cell Transplant Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Goldstein T; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Dhadwal A; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Zarychta K; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Sanchez GM; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Catamero D; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Verina D; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Florendo E; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Yum MH; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • La L; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Gullie J; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Chan E; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Jagannath S; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Chari A; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Am J Hematol ; 95(2): E51-E54, 2020 02.
Article em En | MEDLINE | ID: mdl-31814152
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article